EL
ELV.US Elevance Health Inc
- Market cap
- USD 92.8B
- P/E
- 18.2x
- P/B
- 2.08x
- ROE
- 13.7%
- Dividend yield
- 1.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ELV.US undervalued?
Graham numberELV.US trades 29.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elevance Health Inc fundamental analysis
No fundamental analysis for Elevance Health Inc yet.
Elevance Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elevance Health Inc
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and othe…
Full company profileElevance Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elevance Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 85.0B | 90.0B | 92.1B | 104B | 122B | 139B | 157B | 171B | 177B | 199B | 203B |
| Gross Profit | 18.1B | 17.8B | 20.2B | 22.4B | 33.8B | 36.0B | 40.0B | 47.0B | 49.2B | 50.9B | 82.8B |
| Operating Income | 5.42B | 4.99B | 5.84B | 6.73B | 7.71B | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B | 9.17B |
| EBITDA | 6.19B | 5.59B | 6.95B | 7.86B | 8.18B | 10.0B | 10.1B | 10.5B | 10.5B | 9.66B | 10.5B |
| Net Income | 2.47B | 3.84B | 3.75B | 4.81B | 4.57B | 6.10B | 5.89B | 5.99B | 5.98B | 5.66B | 6.12B |
| EPS | 9.21 | 14 | 15 | 18 | 18 | 25 | 24 | 25 | 26 | 26 | 28 |
| Balance Sheet | |||||||||||
| Total Assets | 66.4B | 71.5B | 72.5B | 78.3B | 88.3B | 97.5B | 103B | 109B | 117B | 121B | 128B |
| Total Liabilities | 41.3B | 45.0B | 43.9B | 46.5B | 55.1B | 61.3B | 66.4B | 69.5B | 75.5B | 77.5B | 83.0B |
| Shareholders' Equity | 25.1B | 26.5B | 28.5B | 31.7B | 33.2B | 36.1B | 36.2B | 39.3B | 41.3B | 43.9B | 44.7B |
| Cash & Short-term Investments | 4.08B | 3.61B | 3.93B | 4.94B | 5.74B | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B | 37.8B |
| Total Debt | 15.7B | 19.9B | 19.2B | 21.2B | 21.8B | 24.9B | 25.8B | 26.7B | 32.7B | 33.2B | 30.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.20B | 4.18B | 3.83B | 6.06B | 10.7B | 8.36B | 8.40B | 8.06B | 5.81B | 4.29B | 10.0B |
| Capital Expenditure | 584M | 790M | 1.21B | 1.08B | 1.02B | 1.09B | 1.15B | 1.30B | 1.26B | 1.12B | 1.05B |
| Free Cash Flow | 2.62B | 3.39B | 2.62B | 4.98B | 9.67B | 7.28B | 7.25B | 6.77B | 4.55B | 3.17B | 8.96B |
| Ratios | |||||||||||
| ROE | 9.8% | 14.5% | 13.1% | 15.2% | 13.8% | 16.9% | 16.3% | 15.2% | 14.5% | 12.9% | 13.7% |
| ROA | 3.7% | 5.4% | 5.2% | 6.1% | 5.2% | 6.3% | 5.7% | 5.5% | 5.1% | 4.7% | 4.8% |
| Net Profit Margin | 2.9% | 4.3% | 4.1% | 4.6% | 3.8% | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% | 3.0% |
| Debt to Equity | 0.63x | 0.75x | 0.67x | 0.67x | 0.66x | 0.69x | 0.71x | 0.68x | 0.79x | 0.76x | 0.69x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elevance Health Inc dividends
- Dividend yield
- 1.65%
- Forward dividend
- 6.88 USD
- Payout ratio
- 27.0%
- Ex-dividend date
- Dec 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.53B | 6.89 | 27.0% |
| 2024 | USD 1.51B | 6.47 | 25.2% |
| 2023 | USD 1.40B | 5.88 | 23.3% |
| 2022 | USD 1.23B | 5.06 | 20.9% |
| 2021 | USD 1.10B | 4.47 | 18.1% |
| 2020 | USD 954M | 3.75 | 20.9% |
| 2019 | USD 818M | 3.14 | 17.0% |
| 2018 | USD 776M | 3.05 | 20.7% |
| 2017 | USD 705M | 2.63 | 18.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 1, 2005.
Who owns Elevance Health Inc
- Insiders 0.30%
- Institutions 94.78%
- Public & others 4.92%
- Shares outstanding 216M
- Free float 216M
Top funds holding ELV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 6.71M | 3.10% | -0.99% | Sep 2026 |
| Vanguard 500 Index Investor | 5.54M | 2.57% | -2.05% | Sep 2026 |
| Vanguard Windsor II Inv | 2.96M | 1.37% | -2.91% | Sep 2026 |
| iShares Core S&P 500 ETF | 2.89M | 1.34% | +0.17% | Oct 2026 |
| First Eagle Global A | 2.84M | 1.32% | 0.00% | Sep 2026 |
| Fidelity 500 Index | 2.82M | 1.30% | -0.02% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 2.64M | 1.22% | -0.25% | Oct 2026 |
| Vanguard Equity-Income Inv | 2.03M | 0.94% | -0.66% | Sep 2026 |
| Vanguard MStar Value Index Investor | 2.01M | 0.93% | -0.56% | Sep 2026 |
| Vanguard Health Care Inv | 1.76M | 0.82% | -5.24% | Sep 2026 |
| Oakmark Investor | 1.60M | 0.74% | -6.22% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.59M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Dividend Growth Inv | 1.26M | 0.58% | 0.00% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 1.19M | 0.55% | -0.19% | Sep 2026 |
| Vanguard Institutional Index I | 1.12M | 0.52% | -1.95% | Sep 2026 |
| CREF Total Global Stock Account R3 | 1.07M | 0.50% | +4.67% | Aug 2026 |
| MFS Value A | 1.06M | 0.49% | -6.26% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 858K | 0.40% | +0.29% | Sep 2026 |
| Artisan Global Value I USD Acc | 848K | 0.39% | +5.61% | Sep 2026 |
| American Funds Washington Mutual A | 687K | 0.32% | 0.00% | Sep 2026 |
Top institutions holding ELV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 19.0M | 8.79% | -4.51% | Jun 2026 |
| Vanguard Capital Management, LLC | 14.1M | 6.51% | -2.00% | Jun 2026 |
| State Street Corp | 10.4M | 4.83% | +1.34% | Jun 2026 |
| Wellington Management Company LLP | 9.21M | 4.26% | +11.97% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 8.38M | 3.88% | +102.71% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.21M | 2.88% | -2.23% | Jun 2026 |
| Sanders Capital, LLC | 5.83M | 2.70% | +0.10% | Sep 2026 |
| Geode Capital Management, LLC | 5.17M | 2.39% | -0.51% | Jun 2026 |
| Harris Associates L.P. | 4.92M | 2.28% | +2.67% | Jun 2026 |
| Artisan Partners Limited Partnership | 4.58M | 2.12% | -10.65% | Jun 2026 |
| Amvescap Plc. | 4.23M | 1.96% | -12.11% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.01M | 1.86% | -15.41% | Jun 2026 |
| NORGES BANK | 3.96M | 1.83% | +31.15% | Jun 2026 |
| Bank of New York Mellon Corp | 3.22M | 1.49% | +13.27% | Jun 2026 |
| FMR Inc | 3.13M | 1.45% | +58.51% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.61M | 1.21% | -0.89% | Jun 2026 |
| Northern Trust Corp | 2.11M | 0.98% | -1.99% | Jun 2026 |
| Citigroup Inc | 2.10M | 0.97% | +777.90% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 2.07M | 0.96% | -17.99% | Jun 2026 |
| Hotchkis & Wiley Capital Management LLC | 2.02M | 0.93% | -8.00% | Jun 2026 |
Elevance Health Inc company profile
- Company name
- Elevance Health Inc
- Ticker
- ELV.US
- Exchange
- USA Stocks
- Listed since
- Jan 2, 2001
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 96,129
- Fiscal year end
- December
- Address
- 220 Virginia Avenue, Indianapolis, IN, United States, 46204
- Phone
- 833 401 1577
- Website
- elevancehealth.com
About Elevance Health Inc
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Elevance Health Inc management
10- Ms. Gail Koziara BoudreauxPresident, CEO & Director · born 1961
- Mr. Mark Bradley KayeExecutive VP & CFO · born 1980
- Mr. Peter David Haytaian Esq.Special Advisor · born 1970
- Mr. Charles Morgan Kendrick Jr.EVP and President of Commercial & Specialty Health Benefits · born 1966
- Ms. Felicia Farr NorwoodExecutive VP & Chief Health Benefits Officer · born 1960
- Mr. Scott Wayne AnglinSVP, Treasurer & Chief Investment Officer
- Mr. Ronald William PenczekSenior VP, Controller & Chief Accounting Officer · born 1965
- Mr. Nathan Allen RichVice President of Investor Relations
- Ms. Erin M. WesslingExecutive VP & Chief Legal Officer · born 1978
- Ms. Julie GoonSenior Vice President of Public Affairs